Sage Journals: Discover world-class research

Abstract

Hypertension and stroke are highly prevalent risk factors for cognitive impairment and dementia. Alzheimer's disease (AD) and vascular dementia (VaD) are the most common forms of dementia, and both conditions are preceded by a stage of cognitive impairment. Stroke is a major risk factor for the development of vascular cognitive impairment (VCI) and VaD; however, stroke may also predispose to AD. Hypertension is a major risk factor for stroke, thus linking hypertension to VCI and VaD, but hypertension is also an important risk factor for AD. Reducing these two major, but modifiable, risk factors—hypertension and stroke—could be a successful strategy for reducing the public health burden of cognitive impairment and dementia. Intake of long-chain omega-3 polyunsaturated fatty acids (LC-n3-FA) and the manipulation of factors involved in the renin-angiotensin system (e.g. angiotensin II or angiotensin-converting enzyme) have been shown to reduce the risk of developing hypertension and stroke, thereby reducing dementia risk. This paper will review the research conducted on the relationship between hypertension, stroke, and dementia and also on the impact of LC-n3-FA or antihypertensive treatments on risk factors for VCI, VaD, and AD.

Keywords

animal models cerebral hemodynamics cognitive impairment dementia diet hypertension

INTRODUCTION

The term dementia comprises several symptoms, for example, a progressive loss of memory and behavioral changes, which together interfere with independent performance of tasks of daily life.¹ As a result of increasing life expectancy, dementia is developing into one of the major public health problems in our aging society. This is driven mostly by the increasing prevalence of Alzheimer's disease (AD) with increasing age. Alzheimer's disease and vascular dementia (VaD) are the number one and number two disorders in terms of prevalence, and together they are responsible for most cases of dementia.^2,3 These disorders are preceded by a stage in which the individual shows cognitive decline but is still able to maintain independent functioning. In AD, this stage is referred to as mild cognitive impairment (MCI) due to AD, whereas in VaD this prodromal stage is termed vascular cognitive impairment (VCI). In this review, the term AD will mostly reflect the continuum of mild cognitive impairment due to AD and dementia due to AD, and the term VaD will reflect the continuum of VCI and VaD.

Historically, AD and VaD have been considered as separate entities, and this separation remains driven by clinical classification criteria. Therefore, the inclusion of AD in a review discussing vascular aspects of dementia may seem confusing. However, there is considerable overlap between these disorders, and the underlying interactions between VaD and AD will be explained and summarized. Furthermore, two major risk factors for VaD and AD, hypertension and stroke, will be further discussed to demonstrate their impact on both types of dementia. Studies involving long-chain omega-3 polyunsaturated fatty acids (LC-n3-FA) supplementation and manipulation of the renin-angiotensin system (RAS) have shown that these novel therapeutic approaches have the potential to lower the effect of hypertension and stroke. Therefore, these new preventive strategies against two major risk factors for cognitive impairment and dementia will be discussed.

MATERIALS AND METHODS

Search Strategy and Selection of the Papers

We searched both the PubMed and Web of Science databases for original and review articles published in English from 1987 until 22 August 2013. The main search topics concerned the classification of AD and VaD, risk factors for both types of dementia, impact of hypertension and stroke on both AD and VaD, and also preventive strategies against dementia, such as long-chain omega-3 polyunsaturated fatty acids and the RAS. The search strategy was based on these search terms: dementia, AD, VaD, VCI, murine and human studies, hypertension, stroke, preventive strategies against dementia (long-chain omega-3 polyunsaturated fatty acids and the RAS). Moreover, to identify potentially relevant new papers, we filtered our total list of relevant papers by hand. Based on the title and abstract, we selected the studies. If these two components were not sufficient for selection, we purchased and evaluated the total publication.

RESULTS

Vascular Dementia, Classification, and Etiology

About 5% to 20% of dementia cases in the population are based on VaD,⁴ which is a common disorder in the elderly but also prevalent among younger adults.⁵ The concept of VaD consists of two main elements: the presence of a dementia syndrome and an underlying vascular cause.⁶ To characterize VaD, criteria of State of California Alzheimer's Disease Diagnostic and Treatment Centers and the National Institute for Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neurosciences are commonly used.^4,6,7 Dementia caused by ischemic or hemorrhagic cerebrovascular disease (CVD) or by ischemic–hypoxic brain lesions of cardiovascular origin is also included in VaD.^5,8 Among recurrent or first-ever stroke patients, poststroke dementia is a frequent sequel, ranging from 6% to 31.8%.^9-11

Definitions of vascular dementia and vascular cognitive impairment

The dementia stage of VaD can also be understood as the most severe form of VCI.^4,12 Vascular cognitive impairment is a syndrome characterized by the presence of clinical stroke or vascular brain injury and cognitive impairment affecting more than one cognitive domain.¹³ The VCI–VaD continuum can be divided into familial and sporadic forms.¹³ The most frequent subtype of familial VaD, caused by genetic mutations, is ‘cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy’ (CADASIL)¹³ caused by mutations in the Notch3 gene.¹⁴ Sporadic VaD has three major subtypes: multiinfarct dementia, strategic infarct dementia, and subcortical vascular encephalopathy (synonymous with Binswanger's disease).¹³ O'Brien¹⁵ has published an alternative classification of the VaD subtypes:^5,15 multi-infarct dementia (cortical VaD); small vessel dementia (subcortical VaD); strategic infarct dementia; hypoperfusion dementia; hemorrhagic dementia; AD with CVD; and the familial variant of VaD, CADASIL.

Stroke and Vascular dementia

Many stroke patients show a gradual but continuous deterioration after a single-stroke lesion.¹⁶ This deterioration is characterized clinically by cognitive and behavioral dysfunction. Stroke research has traditionally focused on motor impairment (e.g. limb paresis), where a number of patients show partial recovery indicating the brain's capacity for repair or compensation after injury.¹⁷ However, this research has paid little attention to cognitive and behavioral deficits induced by stroke. After stroke, recovery from these deficits is often absent, and, as indicated, in many patients stroke leads to progressive deterioration even in the absence of new stroke lesions. Novel research indicates that stroke-induced lesions in brain networks are responsible for this absence of recovery or even for progressive disease, leading to an increased mortality rate.¹⁸ However, it is still not fully understood how stroke, cognitive decline, and dementia are interconnected. Stroke may predispose older adults to developing VaD.

Alzheimer's Disease, Definition and Etiology

In 1906, Alois Alzheimer mentioned arteriosclerotic changes in cerebral blood vessels of the postmortem brain of his 55-year old patient Auguste D(eter) besides the neuropathologic hallmarks, amyloid plaques and neurofibrillary tangles.^19,20 The production of Aβ peptides is increased in familial forms of AD and is thought to be the primary driving force in non-familial (sporadic) AD pathogenesis.²¹ This amyloid cascade hypothesis is still the dominant theory for the pathogenesis of AD, but remains under debate, as other researchers casted doubt that the Aβ plaques and the NFTs are really the main cause of the neurodegeneration in AD.²² Experimental results showed that the density of senile Aβ plaques can be the same in patients affected by AD and in non-affected patients.^23,24 Recently, the focus of the research on amyloid beta has shifted towards the oligomerization of Aβ, as several studies showed that these oligomers and fibrils are in fact the toxic forms of Aβ-peptides.²⁵

Cerebral amyloid angiopathy and Alzheimer's disease

The accumulation of Aβ in the walls of arteries and arterioles in the leptomeninges and cerebral cortex is called cerebral amyloid angiopathy (CAA).²⁶ Cerebral amyloid angiopathy has been linked to hemorrhages (microbleeds), most clearly shown in a mouse model for CAA.²⁷ Because CAA is found both in sporadic AD patients and in cognitively normal individuals without prodromal AD,^28,29 the exact relationship between AD and CAA remains uncertain.

Risk Factors for Vascular Dementia

The assumption has been made that risk factors for VCI and VaD would be the same as those for stroke.³⁰ The risk factors for stroke can be divided into three major classes: non-modifiable (e.g. age, sex, genetic factors, etc.); modifiable (e.g. hypertension, diabetes, hyperlipidemia, atrial fibrillation, smoking, obesity, etc.); and potentially modifiable (e.g. alcohol abuse, infection).³¹

Hypertension has been shown to be the most common modifiable risk factor for stroke worldwide.^32,33 Large-scale, placebo-controlled clinical trials have shown an association between hypertension and stroke,^34,35 and a linear relationship between blood pressure and stroke mortality has been revealed.³⁶ More specifically, a rise of only 1 mm Hg in systolic blood pressure in treated hypertensive patients increased stroke-related death by 2%.³⁶ A community-based prospective cohort study revealed that incremental increases in blood pressure were linked to an increase in microinfarcts in initially non-demented persons (65 to 80 years of age), but not in the older age group.³⁷

A history of stroke leads to a twofold increase in the risk of dementia in the population older than 65 years,^38,39 and this effect was also confirmed in animal studies.⁴⁰ Combining confirmed AD pathology and cerebral infarcts after autopsy with the test results of cognitive function revealed that AD patients with cerebral infarcts showed more cognitive impairment than patients without cerebral lesions.^41,42 In the population-based Rotterdam Scan Study, 1,015 participants underwent neuropsychological testing and cerebral magnetic resonance imaging and were monitored for dementia during the study period.⁴³ In this study, silent brain infarcts doubled the risk for dementia.⁴³ Furthermore, in subjects without dementia, presence of these infarcts increased the chances of a decline in global cognitive function.⁴³ Thus, an increased risk for incident stroke is associated with cognitive decline and dementia.⁴⁴

Even individuals who are stroke and dementia free, but have a higher risk of developing stroke, have more cognitive deficits compared with individuals with lower stroke risk.⁴⁵ As already mentioned for VaD, stroke may also predispose older adults to developing AD. The mechanisms behind cognitive decline after the occurrence of a stroke could help us develop new treatments to prevent the onset of dementia. Furthermore, new preventative treatments for stroke are needed to counteract both stroke and dementia. A possible way to reduce stroke would be to reduce modifiable risk factors such as lifestyle, hypertension, diabetes, hyperlipidemia, atrial fibrillation, smoking, obesity, etc.

Risk Factors for Alzheimer's Disease

Several vascular risk factors for the development of AD have been demonstrated—for example, hypertension, diabetes mellitus, atherosclerosis, atrial fibrillation, coronary artery disease, smoking, obesity, and metabolic syndrome.^46,47 Many studies have shown the association between increased blood pressure in mid-life and cognitive decline or AD in late life,^48,49 although conflicting studies have been reported as well. Associated with increased levels of cardiovascular risk factors,⁵⁰ the apolipoprotein E ∊4 allele represents a strong genetic risk for AD.¹² Notably, among all vascular risk factors, hypertension seems to be the most powerful risk factor for AD.⁵¹ Furthermore, recent studies demonstrated that in the elderly a history of stroke can double the prevalence of AD.⁵² The combination of the latter results demonstrates the impact of these two risk factors for AD.

The risk factors for AD are almost the same as those for VaD. Therefore, in the next paragraph the overlap and interactions of VaD and AD, as well as between their risk factors, are discussed.

Overlap and Interactions of VaD and AD, and their Risk Factors

In the first instance, it may seem difficult to see the overlap between VaD and AD, as these entities are strictly separated in terms of their clinical criteria. As a first illustration of why VaD and AD can no longer be strictly separated in this way, Biessels et al⁵³ have shown in their systematic review that diabetes as a risk factor may directly influence both vascular and neurodegenerative pathology. Biessels et al⁵³ suggested from mechanistic studies that vascular disease and alterations in glucose, insulin, and amyloid metabolism were connected and may underlie the pathophysiology of both AD and VaD.

There is now more and more awareness that vascular risk factors have a key role in the pathogenesis of AD.⁵⁴ In aged subjects, a relation between vascular risk factors and AD has been found.^55,56 In addition, other epidemiologic and clinical studies identified that AD and VaD share common risk factors such as hypertension, diabetes mellitus, hyperlipidemia, and arrhythmia.^57-62 This overlap in major risk factors for these clinically and pathologically different conditions (VaD and AD) may seem confusing when it comes to understanding pathogenesis. However, a simple practical consequence is, for example, that hypertension is a major risk factor for cognitive decline and dementia in the elderly, regardless of whether this is due to stroke, VaD, or AD, or combinations of these disorders. Another overlap between VaD and AD is found in the neurovascular unit. The neurovascular unit is the collective term for neurons, glia, and perivascular and vascular cells.¹² This unit is responsible for the strong increase in cerebral blood flow after cognitive activation. In AD and VCI-VaD patients, the neurovascular unit is disrupted, and this could lead to insufficient perfusion during cognitive activation, contributing to further neuronal dysfunction.^63-67

In addition, alterations in the cerebral microvascular structure are related to AD and VCI.^68,69 In animal models, hypertension, aging, and diabetes, the major risk factors for AD and VCI, interfere with endothelium-dependent responses in the microcirculation and in the functional hemodynamic response of the brain.^12,64,70,71 Furthermore, hypertension promotes atherosclerosis in cerebral arteries⁶⁵ and induces lipohyalinosis, affecting the blood supply to the white matter.⁶⁵ These changes can result in lacunar infarction or brain hemorrhage.⁶⁵ Notably, studies have shown that vascular lesions lead to a decrease in the threshold for the clinical manifestation of AD.¹² In demented and non-demented Japanese-American men, Petrovitch et al⁷² showed that cerebrovascular lesions increase dementia frequency in patients with low neuritic plaque frequency. From this finding, they concluded that the preservation of late-life cognitive function is dependent on the prevention of cerebrovascular lesions.⁷² To support the idea that vascular lesions or CVD lower the threshold for dementia due to AD and α-synucleinopathies, Toledo et al⁷³ demonstrated that CVD is commonly found in aged subjects with dementia, whereas it is even more common in AD patients, especially in younger patients. Furthermore, Toledo et al⁷³ found that the presence of CVD increases the risk for dementia in patients with α-synucleinopathies and also in those being affected by AD.⁷³ These latter studies clearly show the relation between cerebrovascular impairment and dementia, especially AD and VaD.

Hypertension—an overlapping risk factor for vascular dementia and Alzheimer's Disease

Hypertension and Alzheimer's Disease:

One of the most common cardiovascular risk factors, arterial hypertension, has been shown to increase the risk for both AD and VaD.^49,74-81 Skoog and Gustafson⁸⁰ demonstrated a relationship between hypertension and amyloid plaques, neurofibrillary tangles, and brain atrophy. Furthermore, Skoog and Gustafson⁸⁰ showed that increased blood pressure appeared decades before the onset of AD, followed by a decrease in blood pressure years before the start of AD. This phenomenon of hypertension followed by a gradual reduction in blood pressure may be caused by difficulties in maintaining blood pressure homeostasis due to a damaged central nervous system.^80,82 Studies that link blood pressure with dementia may be complicated by this non-stationary course of blood pressure in the trajectory of dementia.

Long-standing hypertension promotes atherosclerosis and vascular remodeling, including increases in wall thickness. Arterial stiffness and severe atherosclerosis can lead to an increase in pulse pressure (the difference between systolic and diastolic blood pressure).⁸³ In a community-based study, increased pulse pressure correlated with a higher risk for AD in older adults.⁸³ In the Rotterdam study, the presence of atherosclerotic plaques or wall thickening has been associated with dementia and its two major subtypes AD and VaD.⁷⁵ Based on that study, arterial stiffening has been suggested to be a key player in the pathogenesis of dementia.⁸⁴ One hypothesis to explain how hypertension is a risk factor for dementia, which follows from these studies, is that hypertension could lead to atherosclerosis and arterial stiffness, which in turn promotes the development of dementia (Figure 1).

Figure 1.

Proposed connections between risk factors, dementia, and possible therapies affecting the major vascular risk factors for Alzheimer's disease (AD) and vascular dementia (VaD), hypertension, and stroke. Hypertension and stroke are major risk factors for dementia, in particular AD and VaD, whereas hypertension itself is also a risk factor for stroke. Despite all research and drug development efforts, no curative pharmacological therapies are available for dementia and also no definitive treatments are attainable for VaD. In human and animal studies, long-chain omega-3 polyunsaturated fatty acids (LC-n3-FA) and the manipulation of factors involved in the renin-angiotensin system (RAS) have shown to be beneficial for lowering the risk of developing dementia like AD and VaD.

Disentangling the possible causal relationships between hypertension, CVD, and Alzheimer's disease in human studies is complex, if not impossible, because vascular risk factors like hypertension may take years or decades to lead to marked cerebrovascular and cognitive symptoms, and because Alzheimer pathology is thought to be present years to decades before clinical symptoms appear. Therefore, animal models are needed to elucidate these mechanisms and translate them to preventive or therapeutic interventions. Poulet et al^85,86 developed an animal model to resemble hypertension-related ‘Alzheimer-like pathology’.^,86 These mice were subjected to high blood pressure, and this resulted in accumulation of amyloid aggregates.^85,86 Hypertension was induced via a coarctation of the aortic arch between the two carotid arteries, causing changes in the CBF, leakage of the blood–brain barrier and neurodegenerative changes.^85,86

However, there may also be a reverse association between AD and hypertension. To investigate the impact of Aβ on blood pressure, in spontaneously hypotensive Sprague–Dawley rats (mean arterial blood pressur ≤ 100 mm Hg) the intra-arterial infusion of Aβ increased the mean arterial blood pressure compared with vehicle distilled water infusion.⁸⁷ This finding suggests that Aβ may be able to induce hypertension, possibly through direct systemic vascular effects, without parenchymal Aβ deposition and before dementia onset.⁸⁷ Taken together, animal studies suggest that Aβ may be responsible for high blood pressure as well as for cerebrovascular impairment. Furthermore, neurodegeneration is due to energetic deficiency and can be explained by Aβ-induced cerebrovascular impairment by, e.g., impairing glucose transport in the hippocampal and cortical neurons.⁸⁸ Hypothetically, these blood pressure and vascular effects of Aβ, which predate cognitive effects, may interact with common vascular disease (e.g., essential hypertension), potentially further elevating blood pressure levels and synergistically inducing cerebrovascular lesions.

Hypertension and Vascular Dementia:

Whereas the link between hypertension and VaD, through the well-established relationship between hypertension and stroke, may seem self-evident, it is often overlooked that in many cases of VaD there is no clear history of stroke. To be more precise, cortical stroke, which is often symptomatic and therefore more easily recognized, is not the most prevalent cause of VaD. VaD is most often caused by lacunar infarcts (e.g., multi-infarct dementia) or severe white matter disease, both related to small vessel disease, and these are frequently clinically unrecognized as acute stroke. As an illustration of this often clinically silent course, lacunar infarcts and white matter disease are frequently found in studies in elderly subjects without known cognitive disorders.^42,89 Depending on the location of these vascular lesions, their extent, and the patient's cognitive reserve, these silent lesions can, however, have sufficient impact to cause VCI or VaD (Figure 1).

Can stroke cause vascular dementia and Alzheimer's disease?

To strengthen the overlap and the connections between AD and VaD, accumulation of amyloid precursor protein and Aβ 1 to 42, hallmarks of AD, has been demonstrated in patients with multiinfarct dementia, which is the most prevalent form of VaD.^90-92 Also, animal studies using models of cerebral ischemia indicated a relationship between the amyloid precursor protein and cerebral ischemia.^90,91,93 A highly sensitive fluorescent RT-PCR assay revealed a significant increase in the peripheral blood expression of amyloid precursor protein mRNA levels among patients who suffered from stroke recently.⁹⁴ A correlation between the density of cortical microinfarcts and the degree of CAA was found in a postmortem analysis of human brains.⁹⁵ Although CAA may occur unrelated to AD, this example serves to explain that AD patients with CAA may present with stroke and cerebrovascular comorbidity.

Endothelin-induced ischemia mimicking small lacunar infarcts in the APP23 AD mouse model increased AD-like pathology and inflammatory markers of AD in the cortex and hippocampus of these transgenic mice.⁴⁰ In another murine study Garcia-Alloza et al⁹⁶ demonstrated that stroke accelerates amyloid deposition via interference with amyloid clearance pathways. Garcia-Alloza et al⁹⁶ examined this association by using a transgenic AD mouse model (APP/PS1) subjected to microstrokes in the middle cerebral artery territory, an experimental stroke model using Rose Bengal dye.⁹⁶ A fast increase in amyloid plaque burden and CAA was measured in the region surrounding the infarction.⁹⁶ As discussed in that paper, these changes were transient -and this may explain why these authors did not find amyloid plaques in postinfarct brain tissue in humans in earlier work.

An association between cerebral hypoperfusion, caused by CAA,^97,98 and cortical microinfarct was demonstrated by Okamoto et al.⁹⁵ Chronic cerebral hypoperfusion due to bilateral common carotid artery stenosis in a CAA mouse model showed that the deposition of Aβ in leptomeningeal vessels was accelerated in combination with the development of microinfarcts.⁹⁵ Notably, in a rat model of AD and cerebral ischemia, the accumulation of amyloid increased the infarct size, neuroinflammation, and also cognitive deficits in these rats.⁹⁹

Hemodynamic changes in vascular dementia and Alzheimer's disease:

A meta-analysis of transcranial Doppler studies has shown that both AD and VaD patients have evident changes in cerebrovascular hemodynamics (mostly reduced CBF and increased cerebrovascular resistance), albeit much more pronounced in VaD patients.¹⁰⁰ A study in transgenic mice overexpressing APP has demonstrated the impact of Aβ on cerebrovascular regulation.¹⁰¹ Using quantitative autoradiography, resting CBF was shown to be reduced in the cerebral cortex and in the hippocampus.¹⁰¹ These APP-overexpressing mice also showed a disturbance in cerebrovascular autoregulation, as they were incapable of maintaining a stable CBF during moderate hypotension or hypertension.¹⁰² Whether this observation can be translated to human AD remains uncertain.¹⁰³

Preventive Strategies—Long-Chain Omega-3 Polyunsaturated Fatty Acids and the Renin-Angiotensin System

Despite all research and drug development efforts, no curative pharmacological therapy is available for dementia and also no definitive treatments are attainable for VaD.⁵ Therefore, to reduce the huge burden of disease, development of preventive strategies is urgent. Considering that vascular disorders contribute importantly to dementia as described above, such preventive strategies could consist of pharmaceutical interventions aimed at vascular dysfunctions (for example, treatment of hypertension and hyperlipidemia). In addition, current studies focus more and more on lifestyle. As already mentioned above, there is growing awareness that lifestyle components, e.g. diet and exercise, can influence modifiable risk factors such as hypertension, type 2 diabetes, and obesity. These modifiable risk factors affect the vascular system, thereby influencing the risk for dementia, including AD.^49,104-107 Modifying these risk factors via a change in lifestyle may potentially delay the onset of dementia and lead to a decrease in the prevalence and public health burden of dementia.^44,107 Aarsland et al¹⁰⁸ demonstrated in a systematic review that physical exercise may prevent the development of VaD. Ravaglia et al¹⁰⁹ found in a population-based cohort study that physical activity is associated with a lower risk for VaD but not for AD. In the review by Dichgans et al,¹¹⁰ the lifestyle risk factors for VaD, AD, dementia (unspecified), and cognitive impairment are summarized well. Based on epidemiologic studies, they show that VaD and AD share common lifestyle risk factors such as smoking, decreased physical activity, and obesity.¹¹⁰ Furthermore, they also state from the existing epidemiologic studies that insufficient evidence for diet as a potential risk factor for VaD exists, whereas concerning AD an improved dietary behavior was associated with a lower risk for cognitive decline.¹¹⁰

Of the many important lifestyle factors, in this review we focus on (the supplementation of) LC-n3-FAs and its impact on cognition and the development of dementia. In addition, we also concentrate on the impact of these LC-n3-FAs on risk factors for VaD and AD, such as hypertension and stroke, to show that diet could have an impact on the development of both VaD and AD.

In a randomized, double-blind, placebo-controlled trial (van de Rest et al¹¹¹) no effect of supplementation with eicosapentaenoic acid combined with DHA for 26 weeks on mental well-being in independently living older individuals could be detected.

In another randomized, double-blind, placebo-controlled clinical trial (Freund-Levi et al¹¹²) the administration of LC-n3-FA in patients with mild-to-moderate AD did not slow down the cognitive decline. However, in a small subgroup of patients with very mild AD, this administration led to beneficial effects.¹¹² A 24-week supplementation with 900 mg/day DHA led to improved learning and memory function in age-related cognitive decline.¹¹³

Many of these clinical trials had a relatively short duration of supplementation of LC-n3-FA or focused only on moderate or advanced AD patients. A systematic review with a meta-analysis in animal models of AD focusing on the effects of long-term LC-n3-FA supplementation on cognitive impairment, amyloid-β pathology, and neuronal loss revealed reduced Aβ burden, improved cognitive function, and decreased neuronal loss.¹¹⁴ A very recent, double-blind, randomized interventional study has shown that the intake of LC-n3-FA in healthy older adults significantly increased executive functions.¹¹⁵ Furthermore, Witte et al¹¹⁵ demonstrated that this intake had also beneficial effects on microstructural integrity and gray matter volume in the frontal, temporal, parietal, and limbic areas, and on carotid intima media thickness and diastolic blood pressure.

Long-chain omega-3 polyunsaturated fatty acids and blood pressure

As already mentioned in the previous paragraph, Witte et al¹¹⁵ were able to show that in healthy older adults the LC-n3-FA supplementation led to a significant decrease in diastolic blood pressure. In addition, a meta-analysis of 31 placebo-controlled trials in 1,356 subjects revealed a dose-response effect of LC-n3-FA leading to a decrease in blood pressure.¹¹⁶ This beneficial blood pressure-lowering effect was even most prominent in hypertensive subjects and in patients with atherosclerosis or hypercholesterolemia.¹¹⁶ This is in accordance with another study showing a reduction in blood pressure in untreated hypertensive patients with daily administration of LC-n3-FA.¹¹⁷ However, the use of LC-n3-FA as antihypertensive treatment in humans needs to be analyzed in long-term studies. Long-term administration of DHA inhibits the development of hypertension in stroke-prone spontaneously hypertensive rats, a model for hypertension and stroke¹¹⁸ Notably, DHA also prolonged the life span of spontaneously hypertensive rats.¹¹⁸ However, not only DHA but other factors also may lower blood pressure. A meta-analysis of 25 randomized controlled trials revealed that an increased intake of dietary fibers also reduces blood pressure in hypertensive patients.¹¹⁹ Reducing dietary salt intake may also be beneficial, as high salt intake increased the mortality rate, raised blood pressure, and increased the number of cerebral aneurysms in spontaneously hypertensive rats.¹²⁰ Also in humans, evidence supports the idea that reducing dietary salt intake can reduce hypertension-related disease.¹²¹

Long-chain omega-3 polyunsaturated fatty acids and stroke

As mentioned above, fish consumption is recommended to reduce the risk for cardiovascular diseases.¹²² Therefore, it is likely to reduce the risk of developing stroke as well. A meta-analysis performed by He et al¹²³ revealed that very low fish consumption protects against the incidence of ischemic stroke. De Goede et al¹²⁴ demonstrated a relationship between higher eicosapentaenoic acid-DHA and lower stroke risk for women, whereas for men these associations were not statistically significant. Intraperitoneal pretreatment with DHA helped to reduce brain infarctions in Sprague-Dawley rats.¹²⁵ Moreover, Ozen et al¹²⁶ demonstrated a protective effect against cerebral ischemia in rats fed with a standard diet plus LC-n3-FA, including eicosapentaenoic acid and DHA. These rats had a reduced number of apoptotic neurons in the prefrontal cortex. This effect of DHA may be mediated by neuroprotectin 1. Docosahexaenoic acid is the precursor of neuroprotectin 1, and aspirin activates the synthesis of aspirin-triggered neuroprotectin 1.¹²⁷ After the occlusion of the middle cerebral artery in Sprague–Dawley rats, inducing an experimental stroke, the administration of synthetic neuroprotectin 1 attenuated cerebral ischemic injury.¹²⁷ In women, intake of LC-n3-FA was associated with a lowered risk for total stroke, whereas dietary cholesterol was positively associated with risk for total stroke and cerebral infarction.¹²⁸ Increased intake of a Mediterranean-style diet was associated with a lowered risk for ischemic stroke, myocardial infarction, and vascular death.¹²⁹ The reduction in cardiovascular morbidity was most prominent for stroke, and was attributed to high intake of olive oil or nuts. However, not only this diet originating around the Mediterranean Sea but other factors also seem to have an influence on stroke incidence. A population-based case–control study performed in southern Sweden demonstrated that stroke risk decreased with fat-fish intake, and especially in women the consumption of lean fish increased the stroke risk.¹³⁰ Additionally, a deficient intake of alpha-linolenic acid, the plant-derived LC-n3-FA, may also be a risk factor for the development of stroke.¹³¹ This is in line with a murine study on rapeseed oil-enriched diets (rapeseed oil is a rich source of alpha-linolenic acid). After middle cerebral artery occlusion, the rapeseed oil-fed groups demonstrated a decreased mortality rate, lowered levels of lipid peroxidation, and a reduced infarct size.¹³² A metaanalysis by Arab et al¹³³ showed that individuals consuming three cups of either green or black tea daily had a 21% lower risk for stroke than those with a daily consumption of less than one cup of tea. In summary, in human and animal studies, LC-n3-FA have shown beneficial effects on stroke and also on hypertension, lowering the risk for dementia, see Tables 1 and 2 and also Figure 1.

Table 1.

Animal studies: summary of intervention trials (LC-n3-FA and the manipulation of factors involved in the RAS)

Study	Species	Model	Sex	Supplement + Dose	Route of administration	Start supplementation	Duration of supplementation	Results
LC-nC-nA
¹²⁷	Rat	Focal cerebral I/R	M	1. 333 mg/kg of AT- NPD1 in SS 2. 333 mg/kg of AT- NPD1 in Me 3. Vehicle	Intravenously	–	3 hours before ischemia	• AT-NPD1 reduces brain infarction size + brain edema • Improved tissue matrix • White matter protection
¹¹⁸	Rat	SHRSP	?	1.	1% DHA 2. 5% DHA 3. Control diet	Diet	6 weeks of age	14 weeks	• DHA has antihypertensive action • DHA ↑ acetylcholine levels • DHA ↑ life span
¹³²	Mouse	Focal cerebral I/R	M	1. 5% RSO 2. 10% RSO 3. 20% RSO 4. 5% palm oil	Diet	—	for 4 or 6 weeks before ischemia	• Groups 2 + 3: decreased mortality rate, lowered levels of lipid peroxidation, and a reduced infarct size
¹²⁶	Rat	Focal cerebral I/R	M	1. Control 2. Marincap capsule (EPA 18%, DHA 12%)	Gavage	8-12 weeks of age	2 weeks before ischemia	• ↓ In apoptotic neurons in the prefrontal cortex in rat group given marincap capsules
125	Rat	Focal cerebral I/R	M	1. 100 nmol/kg 2. 500 nmol/kg 3. Vehicle	Intraperitoneally	—	1. Once 1 hour before ischemia 2. Once 3 days before ischemia 3. Daily for 6 weeks before ischemia	• In all DHA-injected animal groups: reduced infarct volume
Manipulation of the RAS
¹⁴¹	Mouse	ApoE KO + HCD + focal cerebral I/R	M	1. Telmisartan (0.3 mg/kg per day)	Osmotic mini pump	14 weeks of age	For 2 weeks before ischemia	• Telmisartan ↓ ischemic brain area, neurologic deficit, reduction of cerebral blood flow in the penumbra
¹³⁹	Mouse	Aβ 1-40 injection	M	1. C21 (1.0 mg/kg per day) 2. C21 (10.0 mg/kg per day) 3. Vehicle	Intraperitoneally	10-12 weeks of age	for 2 weeks before MWM	• C21 prevented cognitive decline in this AD mouse model
¹³⁷	Mouse	APP23 mice	M	1. Olmesartan (1.0 mg/kg per day) 2. Vehicle	Orally	8 weeks of age	Daily for 4-5 weeks	• ARB olmesartan decreased oxidative stress in cerebral microvessels
¹³⁷	Mouse	Aβ 1-40 injection	M	1. Olmesartan (0.5 mg/kg per day) 2. Olmesartan (1.0 mg/kg per day) 3. Vehicle	Orally	7-8 weeks of age	for 4 weeks before Aβ injection	• Olmesartan completely prevented Aβ-induced vascular dysregulation and ↓ impairment of the hippocampal synaptic plasticity
¹³⁸	Mouse	Aβ 1-40 injection	M	1. Telmisartan (0.35 mg/kg per day) 2. Telmisartan (0.35 mg/kg per day) + GW9662 3. Vehicle	Orally	8 weeks of age	for 4 weeks before Aβ injection	• ↓ of Aβ 1-40 concentration by telmisartan • Telmisartan ↑ CBF • Telmisartan improved Aβ- induced cognitive decline
¹⁴⁴	Mouse	Tg2576 AD mouse model	M	1. Valsartan (10.0 mg/ kg per day) 2. Valsartan (40.0 mg/ kg per day) 3. Water	Orally	6 months of age	for 5 months	• Valsartan ↓ AD-type neuropathology • Valsartan ↓ development of Aβ-mediated cognitive deterioration
¹³⁵	Mouse	Aβ 25-35 injection	M	1. Perindopril (0.1, 0.3 or 1 mg/kg per day) 2. Imidapril (0.3, 1 or 3 mg/kg per day) 3. Enalapril (1, 3 or 10 mg/kg per day) 4. Vehicle	Orally	5-6 weeks of age	After Aβ 25-35 injection daily for 5 consecutive days	• Perindopril ameliorated the cognitive impairment in the AD model mice through inhibition of brain ACE activity

ACE, angiotensin-converting enzyme; AD, Alzheimer's disease; APP, amyloid precursor protein; ARB, angiotensin receptor blocker; AT-NPD1, aspirin-triggered NPD1; C21, compound 21; CBF, cerebral blood flow; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; HCD, high-cholesterol diet; I/R, ischemia reperfusion; KO, knockout; LC-n3-FA, long-chain omega-3 polyunsaturated fatty acids; ME, methyl ester; MWM, Morris water maze; NPD1, neuroprotectin 1; RAS, renin-angiotensin system; RSO, rapeseed oil; SS, sodium salt.

Table 2.

Human studies: summary of intervention trials (LC-n3-FA, and the manipulation of factors involved in the RAS)

Study	Age	Subjects	Sex	N	Supplement + dose/intake	Route of administration	Duration of supplementation	Results
LC-C3-FA
¹³¹	20-65 years	Healthy subjects	M + F	20,069	• Habitual diet was assessed with a validated 178-item food frequency questionnaire	Orally		• Higher ALA intake ↓ risk of stroke
¹²⁴	20-65 years	Healthy subjects	M + F	20,069	• Intake of EPA-DHA was registered	Orally		• Women: higher EPA- DHA and fish intake ↓ stroke risk• Men: no association
¹¹²	74 ± 9 years	Patients with mild-to- moderate AD	M + F	204	1. 1.7g/day DHA2. 0.6 g/day EPA3. Placebo	Orally	6 months	• No delay in the rate of cognitive decline (MMSE/ cognitive portion of ADAS)• In very mild AD patients ↓ in cognitive decline (MMSE)
¹²⁹	69^± 10 years	Healthy subjects	M + F	2,568	• Mediterranean-style diet registered by questionnaire	Orally	—	• Mediterranean-style diet ↓ ischemic stroke, myocardial infarction, and vascular death
¹²⁸	49-83 years	Healthy subjects	F	34,670	• Intake of LC-n3-FA was registered• Intake of cholesterol was registered	Orally	—	• LC-n3-FA ↓ risk of stroke• Cholesterolj risk of stroke
¹³⁰	43-85 years	Healthy + Stroke patients	M + F	5,191	• Fish intake was reported retrospectively	Orally	—	• Fat fish ↓ risk of ischemic stroke• Women: lean fish ↑ risk of stroke
¹¹¹	≥65 y	Nondepressed, older individuals	M + F	302	1. 1.8 g/day EPA + DHA2. 0.4 g/d EPA + DHA3. Placebo	Orally	26 weeks	• Plasma concentrations of EPA + DHA ↑ in both test groups• No effect on mental well-being
¹¹⁵	50-75 years	Healthy subjects	F	30	1. (1.32 g EPA + 0.88 g DHA + 15 mg vitamin E)/day2. Placebo	Orally	26 weeks	• ↑ Executive functions• positive effects on white matter microstructure, gray matter volume, and vascular markers• ↓ in diastolic blood pressure
¹¹³	≥55 years	Healthy subjects	M + F	485	1. 0.9g/day DHA2. Placebo	Orally	24 weeks	• ↑ learning and memory function in ARCD
Manipulation of the RAS
¹³⁶	57 ± 10 years	Patients with manifested atherosclerotic disease	M + F	575	• Blood pressure + use of antihypertensive drugs was registered	—	—	• Untreated hypertension, poorly controlled hypertension, and high BP levels associated with ↓ pCBF• treatment with ARBs leads to less decline in pCBF than other antihypertensives
¹⁴³	70-89 y	Hypertensive patients	M + F	1,518	1. Candesartan (8 mg/day)2. Placebo	Orally	3-5 y	• ARB candesartan ↓ relative risk of stroke
¹⁴²	1.	70 ±9 y 2.	65 ± 11 y	1. Patients with CAD2. Patients without CAD	M + F	1. 7072. 2,324	• Blood pressure + use of antihypertensive drugs + occurrence of cardiovascular and cerebrovascular events was registered	—	—	• Valsartan prevented more cardio-cerebro- vascular events than conventional non-ARB treatment in high-risk hypertensive patients• Valsartan ↓ prevalence of stroke

AD, Alzheimer's disease; ADAS, Alzheimer's disease assessment scale; ALA, alpha-linolenic acid; ARB, angiotensin receptor blocker; ARCD, age-related cognitive decline; BP, blood pressure; CAD, coronary artery disease; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LC-n3-FA, long-chain omega-3 polyunsaturated fatty acids; MMSE, mini-mental state examination; pCBF, parenchymal cerebral blood flow; RAS, renin-angiotensin system.

Manipulation of the renin-angiotensin system—another possible therapy

The renin-angiotensin system is important not only in the cardiovascular system but also in the central nervous system. Angiotensin II binds to two main receptors, type 1 (AT₁) and type 2 (AT₂). Angiotensin type 2 receptors are found in the cerebral regions involved in the control and learning of motor activity.¹³⁴

In Aβ-injected mice, the cognitive impairment was ameliorated by perindopril, a centrally active angiotensin-converting enzyme inhibitor.¹³⁵ In these mice, perindopril inhibited the cerebral, but not the peripheral, ACE activity, demonstrating a beneficial effect on AD as well as on hypertension.¹³⁵ In this animal study, neither imidapril nor enalapril were able to reverse the cognitive impairment in spontaneous alteration and object recognition tests of the AD model mice.¹³⁵ In the SMART-mR study, patients treated with ARBs had less decline in CBF compared with patients treated with other hypertensive drugs (e.g. β-blockers, diuretics, calcium channel blockers, or ACE inhibitors).¹³⁶ In line with this human study, in young AD transgenic mouse models (APP23 mouse), treatment with the ARB olmesartan decreased oxidative stress in cerebral microvessels.¹³⁷ In the same study, Takeda et al¹³⁷ used an acute mouse model induced by intracerebroventricular administration of Aβ 1 to 40, where pretreatment with a low dose of olmesartan completely prevented Aβ-induced vascular dysregulation and also partially reduced the impairment of the hippocampal synaptic plasticity. This preventive effect on cognitive decline by treatment with ARBs in AD was also demonstrated by another animal study performed by Tsukuda et al,¹³⁸ using intracerebroventricular injection of Aβ 1 to 40 in male ddY mice. In these mice, the ARB telmisartan decreased the cerebral Aβ 1 to 40 concentration and enhanced cerebral blood flow.¹³⁸ Furthermore, pretreatment with this ARB reduced the cognitive effects of Aβ 1 to 40 to control level.¹³⁸ Using a similar model, Jing et al¹³⁹ demonstrated that the direct stimulation of the AT2 receptor by a newly generated AT2 receptor agonist, Compound 21 (C21), prevented cognitive decline. In an observational study on cognitive function and systolic blood pressure reduction (OSCAR), in more than 60,000 hypertensive patients, the specific use of the ARB eprosartan led to a reduction in blood pressure and also improved the cognitive function, revealing a positive correlation between cognitive decline or dementia and blood pressure levels.¹⁴⁰

Angiotensin receptor blockers do not only have the potential to reduce cognitive decline in animal and human studies (Tables 1 and 2). In line with the described beneficial effect of ARBs on dementia, the Systolic Hypertension in the Elderly Program and the Systolic Hypertension in Europe study demonstrated that antihypertensive treatment lowered the risk of developing stroke.^34,35 In addition to the effect of an ARB in hypertension, an animal study showed a beneficial effect of ARBs on stroke.¹⁴¹ After an middle cerebral artery occlusion in apolipoprotein E-deficient mice—an atherosclerosis mouse model—treated with a cholesterol-high diet, the administration of the ARB telmisartan did not significantly decrease blood pressure but decreased the ischemic area and also the atherosclerotic formation in the proximal aorta and led to improved cerebral blood flow in the penumbra of these treated mice.¹⁴¹ In patients from the Kyoto heart study, who had coronary artery disease, treatment with the ARB, valsartan, lowered the prevalence of stroke compared with non-treated subjects.¹⁴² Antihypertensive treatment with the ARB candesartan in elderly patients with isolated systolic hypertension significantly reduced the relative risk of developing stroke in comparison with other types of antihypertensive treatment, despite little difference in blood pressure reduction.¹⁴³

The potential mechanisms that could explain the link between hypertension and the development of AD need further investigation. Most human studies are epidemiologic studies that show cross-sectional or longitudinal associations between hypertension and AD, but mechanistic studies or interventional studies are sparse (Table 2). In animal studies, the focus of research has been mainly on the effect of low-dose blood pressure-lowering medication on Aβ accumulation and cognition. These preclinical studies indicate the possible potential for antihypertensive drugs against AD pathology and cognitive decline in AD patients.¹⁴⁴ Indeed, in a systematic review Shah et al¹⁴⁵ mentioned the need for large randomized clinical trials to explore the connection between blood pressure-lowering medications and dementia in humans.

CONCLUSIONS

Many studies have shown that AD, VaD, and stroke share hypertension as a common risk factor, whereas stroke in itself is also a risk factor for the development of AD or VaD (Figure 1). Hypertension combined with aging decreases CBF and results in changes in the cerebrovascular structure and function.^43,44 Together, this leads to cognitive decline, white matter changes, increase in Aβ pathology, and dysfunction of the blood–brain barrier, a combination of factors that may well reflect the multifactorial causes of AD in the elderly population.

Notably, an increase in Aβ (regardless of the underlying cause) could lead to changes in cerebrovascular structure and function, and, if combined with treatment for vascular disease, could represent a vicious cycle of aggravated CVD, increasing Aβ pathology, which in turn enhances vascular disease. As detailed, Aβ may increase blood pressure, decrease the amount of vascular endothelial cells, impair vascular function, and decrease CBF, resulting in further neurodegeneration. Thus, elevated Aβ levels due to any cause could explain the association between hypertension, CVD, and AD. Studying the causal relationships between hypertension, CVD, and AD in humans is complex because of the long latency between pathologic changes and clinical symptoms, which may span decades both in vascular disease and AD. Thus, properly designed animal studies that can be validly translated are needed to enlighten the underlying mechanisms and translate them to preventive or therapeutic interventions. In murine studies, induced hypertension led to an increased accumulation of Aβ, neuroinflammation, changed CBF, and disturbed blood–brain barrier. Moreover, animal models for stroke also showed an increased AD-like pathology, such as enhanced amyloid deposition, neuroinflammation, and cognitive deficits. If we consider hypertension and stroke as major risk factors for dementia, both for VaD and AD, there are two possible therapies for dementia. On the one hand, research has revealed that the supplementation with LC-n3-FA reduces the risk of developing hypertension and stroke, thereby also lowering the risk of developing dementia (Figure 1, Tables 1 and 2). On the other hand, the manipulation of factors involved in the RAS-like angiotensin II receptor blockers or ACE inhibitors showed beneficial effects in animal and human studies (Figure 1, Tables 1 and 2).

As a sequel, future research needs to focus more on the role of other (both medical and lifestyle) treatment strategies to lower the risk factors for dementia. Such research could elucidate the importance of reducing the rate of hypertension and stroke. Until now, studies on stroke have concentrated on motor impairment. Therefore, more research is needed that aim at the cognitive and behavioral deficits induced by stroke. This would also help to understand the connection between stroke, cognitive decline, and dementia and to elucidate the differences and overlap between VaD and AD.

DISCLOSURE/CONFLICT OF INTEREST

The authors declare no conflict of interest.

References

Ritchie

Lovestone

. The dementias. Lancet 2002; 360:1759–1766.

Morris

. The nosology of dementia. Neurol Clin 2000; 18:773–788.

Iadecola

Gorelick

. Converging pathogenic mechanisms in vascular and neurodegenerative dementia. Stroke 2003; 34:335–337.

Roman

Tatemichi

Erkinjuntti

Cummings

Masdeu

Garcia

Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43:250–260.

Chen

Yang

Guo

Zhou

Zhu

. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev 2013; 1: CD008900.

Tang

Chan

SSM

Chiu

HFK

Ungvari

Wong

Kwok

TCY

Impact of applying NINDS-AIREN criteria of probable vascular dementia to clinical and radiological characteristics of a stroke cohort with dementia. Cerebrovasc Dis 2004; 18:98–103.

Chui

Victoroff

Margolin

Jagust

Shankle

Katzman

. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 1992; 42:473.

Roman

. Vascular dementia revisited: diagnosis, pathogenesis, treatment, and prevention. Med Clin North Am 2002; 86:477–499.

Madureira

Guerreiro

Ferro

. Dementia and cognitive impairment three months after stroke. Eur J Neurol 2001; 8:621–627.

10.

Pohjasvaara

Erkinjuntti

Ylikoski

Hietanen

Vataja

Kaste

. Clinical determinants of poststroke dementia. Stroke 1998; 29:75–81.

11.

Inzitari

Di Carlo

Pracucci

Lamassa

Vanni

Romanelli

Incidence and determinants of poststroke dementia as defined by an informant interview method in a hospital-based stroke registry. Stroke 1998; 29:2087–2093.

12.

Gorelick

Scuteri

Black

DeCarli

Greenberg

Iadecola

Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42:2672–2713.

13.

Thal

Grinberg

Attems

. Vascular dementia: different forms of vessel disorders contribute to the development of dementia in the elderly brain. Exp Gerontol 2012; 47:816–824.

14.

Joutel

Corpechot

Ducros

Vahedi

Chabriat

Mouton

Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 1996; 383:707–710.

15.

O'Brien

. Vascular cognitive impairment. Am J Geriatr Psychiatry 2006; 14:724–733.

16.

Grant

Adams

. Neuropsychological Assessment of Neuropsychiatric and Neuromedical Disorders. Oxford University Press: USA, 2009.

17.

Thieme

Bayn

Wurg

Zange

Pohl

Behrens

. Mirror therapy for patients with severe arm paresis after stroke—a randomized controlled trial. Clin Rehabil 2012; 27:314–324.

18.

Rutten-Jacobs

Arntz

Maaijwee

Schoonderwaldt

Dorresteijn

Van Dijk

Long-term mortality after stroke among adults aged 18 to 50 years. Cochrane Database Syst Rev 2013; 309:1136–1144.

19.

Alzheimer

. Uber einen eigenartigen schweren Erkrankungsprozeβ der Hirnrinde. Neurologisches Centralblatt 1906; 23:1129–1136.

20.

Maurer

Volk

Gerbaldo

. Auguste D and Alzheimer's disease. Lancet 1997; 349:1546–1549.

21.

Gouras

Tsai

Naslund

Vincent

Edgar

Checler

Intraneuronal A[beta]42 accumulation in human brain. Am J Pathol 2000; 156:15–20.

22.

De la Torre

. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 2004; 3:184–190.

23.

Braak

. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997; 18:351–357.

24.

Braak

Bohl

Reintjes

. Age, neurofibrillary changes, A[beta]-amyloid and the onset of Alzheimer's disease. Neurosci Lett 1996; 210:87–90.

25.

Haass

Selkoe

. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid [beta]-peptide. Nat Rev Mol Cell Biol 2007; 8:101–112.

26.

Vinters

. Cerebral amyloid angiopathy. A critical review. Stroke 1987; 18:311–324.

27.

Winkler

Bondolfi

Herzig

Jann

Calhoun

Wiederhold

K-H

Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J Neurosci 2001; 21:1619–1627.

28.

Arriagada

Marzloff

Hyman

. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology 1992; 42:1681.

29.

Price

Davis

Morris

White

. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging 1991; 12:295–312.

30.

Gorelick

. Risk factors for vascular dementia and alzheimer disease. Stroke 2004; 35:2620–2622.

31.

J-G

Zhou

R-R

Cai

G-J

. From hypertension to stroke: mechanisms and potential prevention strategies. CNS Neurosci Ther 2011; 17:577–584.

32.

Sahathevan

Brodtmann

Donnan

. Dementia, stroke, and vascular risk factors; a review. Int J Stroke 2012; 7:61–73.

33.

. Reducing the global burden of stroke: INTERSTROKE. Lancet 2010; 376:74–75.

34.

SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265:3255–3264.

35.

Staessen

Fagard

Thijs

Celis

Arabidze

Birkenhäger

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350:757–764.

36.

Palmer

Bulpitt

Fletcher

Beevers

Coles

Ledingham

Relation between blood pressure and stroke mortality. Hypertension 1992; 20:601–605.

37.

Schneider

. High blood pressure and microinfarcts: a link between vascular risk factors, dementia, and clinical Alzheimer's disease. J Am Geriatr Soc 2009; 57:2146–2147.

38.

Savva

Stephan

BCM

. Group tAsSVDSR. Epidemiological studies of the effect of stroke on incident dementia. Stroke 2010; 41:e41–e46.

39.

Béjot

Aboa-Eboulé

Durier

Rouaud

Jacquin

Ponavoy

Prevalence of early dementia after first-ever stroke. Stroke 2011; 42:607–612.

40.

Whitehead

Massoni

Cheng

Hachinski

Cimino

Balduini

Triflusal reduces cerebral ischemia induced inflammation in a combined mouse model of Alzheimer's disease and stroke. Brain Res 2010; 1366:246–256.

41.

Heyman

Fillenbaum

Welsh-Bohmer

Gearing

Mirra

Mohs

Cerebral infarcts in patients with autopsy-proven Alzheimer's disease: CERAD, part XVIII. Consortium to establish a registry for Alzheimer's disease. Neurology 1998; 51:159–162.

42.

Snowdon

Greiner

Mortimer

Riley

Greiner

Markesbery

. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997; 277:813–817.

43.

Vermeer

Prins

Den Heijer

Hofman

Koudstaal

Breteler

MMB

. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003; 348:1215–1222.

44.

Brookmeyer

Gray

Kawas

. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998; 88:1337–1342.

45.

Elias

Sullivan

D'Agostino

Elias

Beiser

Framingham stroke risk profile and lowered cognitive performance. Stroke 2004; 35:404–409.

46.

Kalaria

. Similarities between Alzheimer's disease and vascular dementia. J Neurol Sci 2002; 203–204:29–34.

47.

Kalaria

Akinyemi

Ihara

. Does vascular pathology contribute to Alzheimer changes? J Neurol Sci 2012; 322:141–147.

48.

Kivipelto

Helkala

Laakso

Hanninen

Hallikainen

Alhainen

Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001; 322:1447–1451.

49.

Skoog

Nilsson

Persson

Lernfelt

Landahl

Palmertz

15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347:1141–1145.

50.

Eichner

Dunn

Perveen

Thompson

Stewart

Stroehla

Polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 2002; 155:487–495.

51.

Kennelly

Lawlor

Kenny

. Blood pressure and the risk for dementia—A double edged sword. Ageing Res Rev 2009; 8:61–70.

52.

Sun

Qing

Zhou

Dobie

Cai

Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci USA 2006; 103:18727–18732.

53.

Biessels

Staekenborg

Brunner

Brayne

Scheltens

. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006; 5:64–74.

54.

Panza

D'Introno

Colacicco

Basile

Capurso

Kehoe

Vascular risk and genetics of sporadic late-onset Alzheimer's disease. J Neural Transm 2004; 111:69–89.

55.

Latchman

. Herpes simplex virus and risk of Alzheimer's disease. Lancet 1997; 349:1101.

56.

Breteler

MMB

Claus

Grobbee

Hofman

. Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam Study. BMJ 1994; 308:1604–1608.

57.

Posner

Tang

M-X

Luchsinger

Lantigua

Stern

Mayeux

. The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function. Neurology 2000; 58:1175–1181.

58.

Kilander

Andren

Nyman

Lind

Boberg

Lithell

. Atrial fibrillation is an independent determinant of low cognitive function. Stroke 1998; 29:1816–1820.

59.

Ott

Stolk

Hofman

Van Harskamp

Grobbee

Breteler

MMB

. Association of diabetes mellitus and dementia: the Rotterdam study. Diabetologia 1996; 39:1392–1397.

60.

Kivipelto

Helkala

E-L

Laakso

Hanninen

Hallikainen

Alhainen

Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001; 322:1447–1451.

61.

Launer

Ross

Petrovitch

Masaki

Foley

White

Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 2000; 21:49–55.

62.

Nagata

KEN

Sato

Satoh

Watahiki

Kondoh

Sugawara

Hemodynamic aspects of Alzheimer's Disease. Ann N Y Acad Sci 2002; 977:391–402.

63.

Iadecola

. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 2004; 5:347–360.

64.

Iadecola

Davisson

. Hypertension and cerebrovascular dysfunction. Cell Metab 2008; 7:476–484.

65.

Iadecola

Park

Capone

. Threats to the mind: aging, amyloid, and hypertension. Stroke 2009; 40:S40–S44.

66.

Zacchigna

Lambrechts

Carmeliet

. Neurovascular signalling defects in neurodegeneration. Nat Rev Neurosci 2008; 9:169–181.

67.

Zlokovic

. The Blood–brain barrier in health and chronic neurodegenerative disorders. Neuron 2008; 57:178–201.

68.

Kalaria

. Linking cerebrovascular defense mechanisms in brain ageing and Alzheimer's disease. Neurobiol Aging 2009; 30:1512–1514.

69.

Selnes

Vinters

. Vascular cognitive impairment. Nat Clin Pract Neurol 2006; 2:538–547.

70.

Modrick

Didion

Sigmund

Faraci

. Role of oxidative stress and AT1 receptors in cerebral vascular dysfunction with aging. Am J Physiol Heart Circ Physiol 2009; 296:H1914–H1919.

71.

Park

Anrather

Girouard

Zhou

Iadecola

. Nox2-derived reactive oxygen species mediate neurovascular dysregulation in the aging mouse brain. J Cereb Blood Flow Metab 2007; 27:1908–1918.

72.

Petrovitch

Ross

Steinhorn

Abbott

Markesbery

Davis

AD lesions and infarcts in demented and non-demented Japanese-American men. Ann Neurol 2005; 57:98–103.

73.

Toledo

Arnold

Raible

Brettschneider

Xie

Grossman

Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain 2013; 136:2697–2706.

74.

Elias

Wolf

D'Agostino

Cobb

White

. Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am J Epidemiol 1993; 138:353–364.

75.

Hofman

Ott

Breteler

MMB

Bots

Slooter

AJC

Van Harskamp

Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997; 349:151–154.

76.

Kilander

Nyman

Boberg

Hansson

Lithell

. Hypertension is related to cognitive impairment. Hypertension 1998; 31:780–786.

77.

Launer

Masaki

Petrovitch

Foley

Havlik

. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA 1995; 274:1846–1851.

78.

Ruitenberg

Skoog

Ott

Aevarsson

Witteman

JCM

Lernfelt

Blood pressure and risk of dementia: results from the rotterdam study and the Gothenburg H-70 Study. Dement Geriatr Cogn Disord 2001; 12:33–39.

79.

Sharp

Aarsland

Day

Sonnesyn

. Alzheimer's society vascular dementia systematic review GBallard C. Hypertension is a potential risk factor for vascular dementia: systematic review. Int J Geriatr Psychiatry 2011; 26:661–669.

80.

Skoog

Gustafson

. Update on hypertension and Alzheimer's disease. Neurol Res 2006; 28:605–611.

81.

Yoshitake

Kiyohara

Kato

Ohmura

Iwamoto

Nakayama

Incidence and riskfactors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population. Neurology 1995; 45:1161–1168.

82.

Gentile

Poulet

Pardo

Cifelli

Maffei

Vecchione

β-Amyloid deposition in brain is enhanced in mouse models of arterial hypertension. Neurobiol Aging 2009; 30:222–228.

83.

Qiu

Winblad

Viitanen

Fratiglioni

. Pulse pressure and risk of Alzheimer disease in persons aged 75 years and older: A community-based, longitudinal study. Stroke 2003; 34:594–599.

84.

Hanon

Haulon

Lenoir

Seux

M-L

Rigaud

A-S

Safar

Relationship between arterial stiffness and cognitive function in elderly subjects with complaints of memory loss. Stroke 2005; 36:2193–2197.

85.

Carnevale

Lembo

. ‘Alzheimer-like’ pathology in a murine model of arterial hypertension. Biochem Soc Trans 2011; 39:939–944.

86.

Poulet

Gentile

Vecchione

Distaso

Aretini

Fratta

Acute hypertension induces oxidative stress in brain tissues. J Cereb Blood Flow Metab 2005; 26:253–262.

87.

Arendash

Crawford

Bjugstad

Mullan

. Intravascular β-amyloid infusion increases blood pressure: implications for a vasoactive role of β-amyloid in the pathogenesis of Alzheimer's disease. Neurosci Lett 1999; 268:17–20.

88.

Matsubayashi

Shimada

Kawamoto

Ozawa

. Incidental brain lesions on magnetic resonance imaging and neurobehavioral functions in the apparently healthy elderly. Stroke 1992; 23:175–180.

89.

Chodosh

Foulkes

Kase

Wolf

Mohr

Hier

Silent stroke in the NINCDS Stroke Data Bank. Neurology 1988; 38:1674.

90.

Jendroska

Poewe

Daniel

Pluess

Iwerssen-Schmidt

Paulsen

Ischemic stress induces deposition of amyloid beta immunoreactivity in human brain. Acta Neuropathol 1995; 90:461–466.

91.

Jendroska

Hoffmann

Patt

. Amyloid β Peptide and Precursor Protein (APP) in Mild and Severe Brain Ischemia. Ann N Y Acad Sci 1997; 826:401–405.

92.

Kalaria

Bhatti

Palatinsky

Pennington

Shelton

Chan

Accumulation of the beta amyloid precursor protein at sites of ischemic injury in rat brain. Neuroreport 1993; 4:211–214.

93.

Nakamura

Takeda

Niigawa

Hariguchi

Nishimura

. Amyloid β-protein precursor deposition in rat hippocampus lesioned by ibotenic acid injection. Neurosci Lett 1992; 136:95–98.

94.

Pottier

Wallon

Lecrux

Maltete

Bombois

Jurici

Amyloid-β Protein Precursor Gene Expression in Alzheimer's Disease and Other Conditions. JAlzheimers Dis 2012; 28:561–566.

95.

Okamoto

Yamamoto

Kalaria

Senzaki

Maki

Hase

Cerebral hypoperfusion accelerates cerebral amyloid angiopathy and promotes cortical microinfarcts. Acta Neuropathol 2012; 123:381–394.

96.

Garcia-Alloza

Gregory

Kuchibhotla

Fine

Wei

Ayata

Cerebrovascular lesions induce transient β-amyloid deposition. Brain 2011; 134:3697–3707.

97.

Okamoto

Ihara

Fujita

Ito

Takahashi

Tomimoto

. Cortical microinfarcts in Alzheimer's disease and subcortical vascular dementia. Neuroreport 2009; 20:990–996.

98.

Suter

O-C

Sunthorn

Kraftsik

Straubel

Darekar

Khalili

Cerebral hypoperfusion generates cortical watershed microinfarcts in Alzheimer disease. Stroke 2002; 33:1986–1992.

99.

Whitehead

Cheng

Hachinski

Cechetto

. Progressive increase in infarct size, neuroinflammation, and cognitive deficits in the presence of high levels of amyloid. Stroke 2007; 38:3245–3250.

100.

Sabayan

Jansen

Oleksik

Van Osch

MJP

Van Buchem

Van Vliet

Cerebrovascular hemodynamics in Alzheimer's disease and vascular dementia: a meta-analysis of transcranial Doppler studies. Ageing Res Rev 2012; 11:271–277.

101.

Niwa

Kazama

Younkin

Carlson

Iadecola

. Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol Dis 2002; 9:61–68.

102.

Niwa

Kazama

Younkin

Carlson

Iadecola

. Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am J Physiol Heart Circ Physiol 2002; 283:H315–H323.

103.

Claassen

JAHR

Zhang

. Cerebral autoregulation in Alzheimer's disease. J Cereb Blood Flow Metab 2011; 31:1572–1577.

104.

Whitmer

Gunderson

Barrett-Connor

Charles

Quesenberry

Yaffe

. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ 2005; 330:1360.

105.

Luchsinger

Mayeux

. Cardiovascular risk factors and Alzheimer's disease. Curr Atheroscler Rep 2004; 6:261–266.

106.

Kivipelto

Ngandu

Laatikainen

Winblad

Soininen

Tuomilehto

. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol 2006; 5:735–741.

107.

Kalaria

Maestre

Arizaga

Friedland

Galasko

Hall

Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol 2008; 7:812–826.

108.

Aarsland

Sardahaee

Anderssen

Ballard

. The Alzheimer's Society Systematic Review. Is physical activity a potential preventive factor for vascular dementia? A systematic review. Aging Ment Health 2010; 14:386–395.

109.

Ravaglia

Forti

Lucicesare

Pisacane

Rietti

Bianchin

Physical activity and dementia risk in the elderly: findings from a prospective Italian study. Neurology 2008; 70:1786–1794.

110.

Dichgans

Zietemann

. Prevention of vascular cognitive impairment. Stroke 2012; 43:3137–3146.

111.

Van de Rest

Geleijnse

Kok

Van Staveren

Hoefnagels

Beekman

Effect of fish-oil supplementation on mental well-being in older subjects: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2008; 88:706–713.

112.

Freund-Levi

Eriksdotter-Jonhagen

Cederholm

Basun

Faxén-Irving

Garlind

O-3 fatty acid treatment in 174 patients with mild to moderate alzheimer disease: omegad study: a randomized double-blind trial. Arch Neurol 2006; 63:1402–1408.

113.

Yurko-Mauro

McCarthy

Rom

Nelson

Ryan

Blackwell

Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement 2010; 6:456–464.

114.

Hooijmans

Pasker-De Jong

PCM

De Vries

RBM

Ritskes-Hoitinga

. The effects of long-term omega-3 fatty acid supplementation on cognition and Alzheimer's pathology in animal models of Alzheimer's Disease: A Systematic Review And Meta-Analysis. J Alzheimers Dis 2012; 28:191–209.

115.

Witte

Kerti

Hermannstadter

Fiebach

Schreiber

Schuchardt

Long-chain omega-3 fatty acids improve brain function and structure in older adults. Cereb Cortex 2013.

116.

Morris

Sacks

Rosner

. Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation 1993; 88:523–533.

117.

Appel

Miller

3rd Seidler

Whelton

. Does supplementation of diet with ‘fish oil’ reduce blood pressure? A meta-analysis of controlled clinical trials. Arch Intern Med 1993; 153:1429–1438.

118.

Kimura

Saito

Minami

Togashi

Nakamura

Ueno

Docosahexaenoic acid attenuated hypertension and vascular dementia in stroke-prone spontaneously hypertensive rats. Neurotoxicol Teratol 2002; 24:683–693.

119.

Whelton

Hyre

Pedersen

Whelton

. Effect of dietary fiber intake on blood pressure: a meta-analysis of randomized, controlled clinical trials. J Hypertens 2005; 23:475–481.

120.

Zhang

Liu

A-J

Yi-Ming

Liu

J-G

Shen

F-M

D-F

. Pressor and non-pressor effects of sodium loading on stroke in stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 2008; 35:83–88.

121.

Kuller

Shemanski

Manolio

Haan

Fried

Bryan

Relationship between ApoE, MRI findings, and cognitive function in the cardiovascular health study. Stroke 1998; 29:388–398.

122.

Goldstein

Bushnell

Adams

Appel

Braun

Chaturvedi

Guidelines for the primary prevention of stroke. Stroke 2011; 42:517–584.

123.

Song

Daviglus

Liu

Van Horn

Dyer

Fish consumption and incidence of stroke. Stroke 2004; 35:1538–1542.

124.

De Goede

Verschuren

WMM

Boer

JMA

Kromhout

Geleijnse

. Gender-specific associations ofMarine n-3 fatty acids and fish consumption with 10-year incidence of stroke. PLoS ONE 2012; 7:e33866.

125.

Pan

H-C

Kao

T-K

Y-C

Yang

D-Y

Yen

Y-J

Wang

C-C

Protective effect of docosahexaenoic acid against brain injury in ischemic rats. J Nutr Biochem 2009; 20:715–725.

126.

Ozen

Cosar

Sahin

Fidan

Eser

Mollaoglu

The protective effect of fish n-3 fatty acids on cerebral ischemia in rat prefrontal cortex. Neurol Sci 2008; 29:147–152.

127.

Bazan

Eady

Khoutorova

Atkins

Hong

Novel aspirin-triggered neuroprotectin D1 attenuates cerebral ischemic injury after experimental stroke. Exp Neurol 2012; 236:122–130.

128.

Larsson

Virtamo

Wolk

. Dietary fats and dietary cholesterol and risk of stroke in women. Atherosclerosis 2012; 221:282–286.

129.

Gardener

Wright

Demmer

Boden-Albala

Elkind

Mediterranean-style diet and risk of ischemic stroke, myocardial infarction, and vascular death: the Northern Manhattan Study. Am J Clin Nutr 2011; 94:1458–1464.

130.

Oudin

Wennberg

. Fish Consumption and ischemic stroke in Southern Sweden. Nutr J 2011; 10:109.

131.

De Goede

Verschuren

WMM

Boer

JMA

Kromhout

Geleijnse

. Alpha-linolenic acid intake and 10-Year incidence of coronary heart disease and stroke in 20,000 middle-aged men and women in The Netherlands. PLoS ONE 2011; 6:e17967.

132.

Nguemeni

Delplanque

Rovere

Simon-Rousseau

Gandin

Agnani

Dietary supplementation of alpha-linolenic acid in an enriched rapeseed oil diet protects from stroke. Pharmacol Res 2010; 61:226–233.

133.

Arab

Liu

Elashoff

. Green and black tea consumption and risk of stroke. Stroke 2009; 40:1786–1792.

134.

Mogi

J-M

Iwanami

Min

L-J

Tsukuda

Iwai

Angiotensin II type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2. Hypertension 2006; 48:141–148.

135.

Yamada

Uchida

Takahashi

Takayama

Nagata

Suzuki

Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer's disease. Brain Res 2010; 1352:176–186.

136.

Muller

Van der Graaf

Visseren

Mali

WPTM

Geerlings

. for the SSG. Hypertension and longitudinal changes in cerebral blood flow: the SMART-MR study. Ann Neurol 2012; 71:825–833.

137.

Takeda

Sato

Takeuchi

Kurinami

Shinohara

Niisato

Angiotensin receptor blocker prevented β-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling. Hypertension 2009; 54:1345–1352.

138.

Tsukuda

Mogi

Iwanami

Min

L-J

Sakata

Jing

Cognitive deficit in Amyloid-β-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-γ activation. Hypertension 2009; 54:782–787.

139.

Jing

Mogi

Sakata

Iwanami

Tsukuda

Ohshima

Direct stimulation of angiotensin II type 2 receptor enhances spatial memory. J Cereb Blood Flow Metab 2012; 32:248–255.

140.

Shlyakhto

. Observational study on cognitive function and systolic blood pressure reduction (OSCAR): preliminary analysis of 6-month data from>10000 patients and review of the literature. Curr Med Res Opin 2007; 23:S13–S18.

141.

Iwai

Inaba

Tomono

Kanno

Iwanami

Mogi

Attenuation of focal brain ischemia by telmisartan, an angiotensin II Type 1 receptor blocker, in atherosclerotic apolipoprotein E-deficient mice. Hypertens Res 2008; 31:161–168.

142.

Shiraishi

Sawada

Koide

Yamada

Matsubara

. Cardio-Cerebrovascular protective effects of valsartan in high-risk hypertensive patients with coronary artery disease (from the Kyoto Heart Study). Am J Cardiol 2012; 109:1308–1314.

143.

Papademetriou

Farsang

Elmfeldt

Hofman

Lithell

Olofsson

Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension. The study on cognition and prognosis in the elderly (SCOPE). J Am Coll Cardiol 2004; 44:1175–1180.

144.

Wang

Chen

Zhao

Qian

Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest 2007; 117:3393–3402.

145.

Shah

Qureshi

Johnson

Parikh

Schulz

Kunik

. Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. Am J Geriatr Pharmacother 2009; 7:250–261.

Vascular Aspects of Cognitive Impairment and Dementia

Abstract

Keywords

INTRODUCTION

MATERIALS AND METHODS

Search Strategy and Selection of the Papers

RESULTS

Vascular Dementia, Classification, and Etiology

Definitions of vascular dementia and vascular cognitive impairment

Stroke and Vascular dementia

Alzheimer's Disease, Definition and Etiology

Cerebral amyloid angiopathy and Alzheimer's disease

Risk Factors for Vascular Dementia

Risk Factors for Alzheimer's Disease

Overlap and Interactions of VaD and AD, and their Risk Factors

Hypertension—an overlapping risk factor for vascular dementia and Alzheimer's Disease

Hypertension and Alzheimer's Disease:

Hypertension and Vascular Dementia:

Can stroke cause vascular dementia and Alzheimer's disease?

Hemodynamic changes in vascular dementia and Alzheimer's disease:

Preventive Strategies—Long-Chain Omega-3 Polyunsaturated Fatty Acids and the Renin-Angiotensin System

Long-chain omega-3 polyunsaturated fatty acids and blood pressure

Long-chain omega-3 polyunsaturated fatty acids and stroke

Manipulation of the renin-angiotensin system—another possible therapy

CONCLUSIONS

DISCLOSURE/CONFLICT OF INTEREST

References